학술논문
Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison.
Document Type
Article
Author
Cholette, François; Mesa, Christine; Harris, Angela; Ellis, Hannah; Cachero, Karla; Lacap, Philip; Galipeau, Yannick; Langlois, Marc-André; Gingras, Anne-Claude; Yansouni, Cedric P.; Papenburg, Jesse; Cheng, Matthew P.; Chakraborty, Pranesh; Stein, Derek R.; Van Caeseele, Paul; Bartlett, Sofia; Krajden, Mel; Goldfarb, David; McGeer, Allison; Osiowy, Carla
Source
Subject
*ANTIBODY titer
*COVID-19 testing
*NUCLEIC acid amplification techniques
*COVID-19
*DRIED blood spot testing
*VIRAL antibodies
*
*
*
*
*
Language
ISSN
1932-6203
Abstract
The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present several logistical challenges within Canada due its unique geography including rural and remote communities. Dried blood spot (DBS) sampling is a practical solution but comparative performance data on SARS-CoV-2 serological tests using DBS is currently lacking. Here we present test performance data from a well-characterized SARS-CoV-2 DBS panel sent to laboratories across Canada representing 10 commercial and 2 in-house developed tests for SARS-CoV-2 antibodies. Three commercial assays identified all positive and negative DBS correctly corresponding to a sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI = 72.2, 100). Two in-house assays also performed equally well. In contrast, several commercial assays could not achieve a sensitivity greater than 40% or a negative predictive value greater than 60%. Our findings represent the foundation for future validation studies on DBS specimens that will play a central role in strengthening Canada's public health policy in response to COVID-19. [ABSTRACT FROM AUTHOR]